Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.74 |
| ▸ | DRD3 | P35462 | 2/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CASR | P41180 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11583588 | 0.88 | HTR2A (0.66) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Hydrochloric Acid SCHEMBL11679206 | 0.86 | HTR2A (0.63) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Fendiline SCHEMBL14415809 | 0.85 | OPRM1 (1.00) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Fendiline SCHEMBL14415808 | 0.85 | OPRM1 (1.00) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Fendiline SCHEMBL63814 | 0.85 | OPRM1 (1.00) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Fendiline SCHEMBL5053865 | 0.85 | OPRM1 (1.00) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| SCHEMBL14064842 | 0.85 | CYP3A4 (0.55) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Fendiline SCHEMBL15571059 | 0.83 | KMT2A (1.00) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| SCHEMBL6705994 | 0.83 | KCNH2 (0.69) | KCNH2CYP3A4HTR1AADORA3SLC6A2 | |
| Fendiline SCHEMBL666530 | 0.83 | KMT2A (1.00) | KCNH2CYP3A4HTR1AADORA3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1088585-C | Compound active at a novel site on receptor-operated calcium channels usefull for treatment of neurological disorders and diseases | NPS PHARMACEUTICAL CO LTD (US) | 2002-08-07 | — | — | CN | claimed |
| EP-0743853-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMA INC (US) | 2001-05-02 | — | — | EP | claimed |
| CN-119661368-A | Synthesis method of beta-aryl ethyl amine medicine | 闽都创新实验室 | 2025-03-21 | — | — | CN | disclosed |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | NPS PHARMACEUTICALS, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324396-B2 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | AMGEN INC. (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2176247-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | Amgen Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090286693-A1 | MICROARRAYS OF TAGGED COMBINATORIAL TRIAZINE LIBRARIES | NEW YORK UNIVERSITY, NYU MEDICAL CENTER, DEPARTMENT OF INDUSTRIAL LIAISON (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286693-A1 | MICROARRAYS OF TAGGED COMBINATORIAL TRIAZINE LIBRARIES | NEW YORK UNIVERSITY, NYU MEDICAL CENTER, DEPARTMENT OF INDUSTRIAL LIAISON (US) | 2009-11-19 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| JP-2004002437-A | COMPOUND ACTIVE AT NEW POSITION ON RECEPTOR-OPERATED CALCIUM CHANNEL USEFUL FOR TREATING NEUROPRAXIA AND NEUROPATHY | NPS PHARMACEUT INC | 2004-01-08 | — | — | JP | disclosed |
| EP-0743853-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMA INC (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | KCNH2 651/4885CYP3A4 4488/4885HTR1A 277/4885 |
| US-20130190407-A1 | CALCIUM RECEPTOR-ACTIVE MOLECULES | CASR, CALCR, ORAI1 | KCNH2 1123/4885CYP3A4 4804/4885HTR1A 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.